纳武利尤单抗联合伊匹木单抗：一种用于不可切除肝细胞癌的新型一线联合免疫疗法。 - Suppr

Suppr

超能文献

Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma.

作者信息

Kudo Masatoshi

机构信息

Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.

出版信息

Liver Cancer. 2024 Aug 12;13(5):459-467. doi: 10.1159/000540801. eCollection 2024 Oct.

DOI:10.1159/000540801

PMID:39435273

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11493385/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/359b/11493385/35b078560ea0/lic-2024-0013-0005-540801_F03.jpg

相似文献

Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma.

Liver Cancer. 2024 Aug 12;13(5):459-467. doi: 10.1159/000540801. eCollection 2024 Oct.

Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma.

Int J Radiat Oncol Biol Phys. 2023 Jan 1;115(1):202-213. doi: 10.1016/j.ijrobp.2022.09.052. Epub 2022 Sep 13.

Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.

Lancet Gastroenterol Hepatol. 2022 Mar;7(3):208-218. doi: 10.1016/S2468-1253(21)00427-1. Epub 2022 Jan 20.

Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma.

J Comp Eff Res. 2021 Apr;10(5):343-352. doi: 10.2217/cer-2020-0236. Epub 2021 Jan 14.

Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial.

Lancet Oncol. 2023 Nov;24(11):1252-1265. doi: 10.1016/S1470-2045(23)00449-7. Epub 2023 Oct 13.

Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040.

Ann Oncol. 2024 Jun;35(6):537-548. doi: 10.1016/j.annonc.2024.03.005. Epub 2024 May 22.

FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib.

Oncologist. 2021 Sep;26(9):797-806. doi: 10.1002/onco.13819. Epub 2021 Jun 10.

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.

Ann Oncol. 2022 May;33(5):488-499. doi: 10.1016/j.annonc.2022.01.074. Epub 2022 Feb 3.

Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial.

Lancet Oncol. 2023 Apr;24(4):347-359. doi: 10.1016/S1470-2045(23)00053-0. Epub 2023 Feb 28.

Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma.

Front Public Health. 2022 Jul 22;10:947375. doi: 10.3389/fpubh.2022.947375. eCollection 2022.

引用本文的文献

Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial.

Signal Transduct Target Ther. 2025 Aug 6;10(1):249. doi: 10.1038/s41392-025-02333-5.

Systemic Therapy for Unresectable Hepatocellular Carcinoma: Current Landscape and Future Directions.

Int J Mol Sci. 2025 Jun 22;26(13):5994. doi: 10.3390/ijms26135994.

The role of pioneering transcription factors, chromatin accessibility and epigenetic reprogramming in oncogenic viruses.

Front Microbiol. 2025 Jun 16;16:1602497. doi: 10.3389/fmicb.2025.1602497. eCollection 2025.

Treatment Decision-Making in Unresectable Hepatocellular Carcinoma: Importance of Understanding the Different Response Patterns between IO plus Anti-VEGF and IO plus IO Regimens.

Liver Cancer. 2025 Mar 7;14(2):119-126. doi: 10.1159/000545163. eCollection 2025 Apr.

Immune microenvironment and immunotherapy in hepatocellular carcinoma: mechanisms and advances.

Front Immunol. 2025 Apr 2;16:1581098. doi: 10.3389/fimmu.2025.1581098. eCollection 2025.

本文引用的文献

Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040.

Ann Oncol. 2024 Jun;35(6):537-548. doi: 10.1016/j.annonc.2024.03.005. Epub 2024 May 22.

Urgent Global Need for PIVKA-II and AFP-L3 Measurements for Surveillance and Management of Hepatocellular Carcinoma.

Liver Cancer. 2024 Feb 20;13(2):113-118. doi: 10.1159/000537897. eCollection 2024 Apr.

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.

Ann Oncol. 2024 May;35(5):448-457. doi: 10.1016/j.annonc.2024.02.005. Epub 2024 Feb 19.

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.

NEJM Evid. 2022 Aug;1(8):EVIDoa2100070. doi: 10.1056/EVIDoa2100070. Epub 2022 Jun 6.

Current Therapeutic Strategies for Hepatocellular Carcinoma in Japan.

Liver Cancer. 2023 Oct 3;12(6):497-509. doi: 10.1159/000534304. eCollection 2023 Dec.

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.

Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2.

Drug-Off Criteria in Patients with Hepatocellular Carcinoma Who Achieved Clinical Complete Response after Combination Immunotherapy Combined with Locoregional Therapy.

Liver Cancer. 2023 Jul 28;12(4):289-296. doi: 10.1159/000532023. eCollection 2023 Sep.

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.

Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24.

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.

Hepatology. 2023 Dec 1;78(6):1922-1965. doi: 10.1097/HEP.0000000000000466. Epub 2023 May 22.

Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines).

Hepatol Res. 2023 May;53(5):383-390. doi: 10.1111/hepr.13892. Epub 2023 Mar 10.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验